IBRX · ImmunityBio, Inc.
The latest filing states the doubt was alleviated.
“we believe that substantial doubt exists regarding our ability to continue as a going concern without additional funding or financial support. However, we believe our existing cash and cash equivalents, and investments in marketable securities; sales of our approved product; capital to be raised through equity offerings, including but not limited to, the offering, issuance and sale by us of our common stock under our Form S-3ASR shelf registration statement; and our potential ability to borrow from affiliated entities will be sufficient to fund our operations through at least the next 12 months following the issuance date of the condensed consolidated financial statements based primarily upon our Founder, Executive Chairman and Global Chief Scientific and Medical Officer's intent and ability to support our operations with additional funds, including loans from affiliated entities, as required, which we believe alleviates such doubt.”View the 10-Q filed Aug 4, 2026
Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
Equity Offering (ATM) Programs
| Program Established | Last Amended | Capacity | Remaining | Runs Through | Source |
|---|---|---|---|---|---|
| 2021-04 | 2025-12 | $500,000,000 | $349,200,000 as of 2026-06-30 | — | 10-Q , filed 2026-08-04 |
Cash spent on buybacks by quarter
Cash deployed each quarter. Δ marks quarters derived from the company's cumulative year-to-date disclosures.
Repurchase History
| Fiscal Year Ended | Cash Spent | Source |
|---|---|---|
| 2021-12-31 | $0 | 10-K, filed 2022-03-01 |
| 2020-12-31 | $0 | 10-K, filed 2022-03-01 |
| 2019-12-31 | $2,501,000 | 10-K, filed 2022-03-01 |
| 2018-12-31 | $228,000 | 10-K, filed 2021-03-04 |
| 2017-12-31 | $15,227,000 | 10-K, filed 2020-03-25 |
| 2016-12-31 | $15,847,000 | 10-K, filed 2019-03-13 |
| 2015-12-31 | $4,798,000 | 10-K, filed 2018-03-12 |
| 2014-12-31 | $0 | 10-K, filed 2017-03-15 |